In neuropathic pain models including bone cancer pain, chemotherapy-induced peripheral neuropathy, and nerve injury, administration of STING agonists activates STING, increases the expression of IFN-I, and inhibits the excitability of nociceptors in the peripheral nervous system (PNS) (Wang et al., 2021). Here, STING1 is linked to peripheral neuropathy.